Akari Therapeutics (AKTX) Short Interest Ratio & Short Volume → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free AKTX Stock Alerts $1.52 +0.04 (+2.70%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Akari Therapeutics Short Interest DataCurrent Short Volume2,200 sharesPrevious Short Volume600 sharesChange Vs. Previous Month+266.67%Dollar Volume Sold Short$3,388.00Short Interest Ratio / Days to Cover0.1Last Record DateApril 30, 2024Outstanding Shares7,920,000 sharesFloat Size6,590,000 sharesShort Percent of Float0.03%Today's Trading Volume20,155 sharesAverage Trading Volume23,006 sharesToday's Volume Vs. Average88% Short Selling Akari Therapeutics ? Sign up to receive the latest short interest report for Akari Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatAKTX Short Interest Over TimeAKTX Days to Cover Over TimeAKTX Percentage of Float Shorted Over Time Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. Akari Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20242,200 shares $3,388.00 +266.7%0.0%0.1 $1.54 4/15/2024600 shares $720.00 -94.3%0.0%0.1 $1.20 3/31/202410,500 shares $19,582.50 +75.0%0.2%0.9 $1.87 3/15/20246,000 shares $11,820.00 -37.5%0.1%0.6 $1.97 2/29/20249,600 shares $21,216.00 +10.3%0.2%1.1 $2.21 2/15/20248,700 shares $20,706.00 +357.9%0.2%1 $2.38 Get the Latest News and Ratings for AKTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20241,900 shares $4,807.00 -66.7%0.0%0.2 $2.53 1/15/20245,700 shares $16,416.00 +375.0%0.1%0.5 $2.88 12/31/20231,200 shares $3,744.00 -29.4%0.0%0.1 $3.12 12/15/20231,700 shares $4,760.00 -50.0%0.0%0.1 $2.80 11/30/20233,400 shares $10,030.00 -69.6%0.1%0.3 $2.95 11/15/202311,200 shares $35,504.00 -36.0%0.2%0.7 $3.17 10/31/202317,500 shares $61,425.00 +49.6%0.4%0.8 $3.51 10/15/202311,700 shares $42,705.00 -33.5%0.2%0.4 $3.65 9/30/202317,600 shares $69,520.00 +2.9%0.4%0.7 $3.95 9/15/202317,100 shares $62,244.00 +116.5%0.5%0.6 $3.64 8/31/20237,900 shares $24,885.00 -24.8%0.2%0.3 $3.15 8/15/202310,500 shares $39,585.00 -95.7%0.3%0.3 $3.77 7/31/2023243,800 shares $60,852.48 -29.2%N/A0.5 $0.25 7/15/2023344,200 shares $58,961.46 +67.3%N/A0.6 $0.17 6/30/2023205,700 shares $34,948.43 -1.5%N/A0.4 $0.17 6/15/2023208,800 shares $32,760.72 -3.7%N/A0.4 $0.16 5/31/2023216,700 shares $38,334.23 -5.2%N/A0.4 $0.18 5/15/2023228,600 shares $42,153.84 +104.5%N/A0.5 $0.18 4/30/2023111,800 shares $20,246.98 -62.3%N/A0.3 $0.18 4/15/2023296,900 shares $59,409.69 +128.0%N/A0.8 $0.20 3/31/2023130,200 shares $23,657.34 -21.5%N/A0.5 $0.18 3/15/2023165,800 shares $42,776.40 +79.4%N/A1.3 $0.26 2/28/202392,400 shares $31,878.00 +42.2%N/A0.8 $0.35 2/15/202365,000 shares $29,250.00 -30.6%N/A0.7 $0.45 1/31/202393,700 shares $43,739.16 -15.9%N/A1.2 $0.47 1/15/2023111,400 shares $60,111.44 +47.2%N/A1.4 $0.54 12/30/202275,700 shares $35,571.43 -2.1%N/A0.9 $0.47 12/15/202277,300 shares $35,558.00 -43.0%N/A1 $0.46 11/30/2022135,500 shares $74,877.30 -8.2%N/A1.3 $0.55 11/15/2022147,600 shares $84,279.60 +313.5%N/A1.5 $0.57 10/31/202235,700 shares $16,629.06 -44.8%N/A0.4 $0.47 10/15/202264,700 shares $31,470.08 -16.8%N/A0.7 $0.49 9/30/202277,800 shares $49,014.00 +215.0%0.5%0.8 $0.63 9/15/202224,700 shares $16,796.00 -10.5%0.2%0.3 $0.68Elon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. AKTX Short Interest - Frequently Asked Questions What is Akari Therapeutics' current short interest? Short interest is the volume of Akari Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 2,200 shares of AKTX short. 0.03% of Akari Therapeutics' shares are currently sold short. Learn More on Akari Therapeutics' current short interest. What is a good short interest percentage for Akari Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.03% of Akari Therapeutics' floating shares are currently sold short. Is Akari Therapeutics' short interest increasing or decreasing? Akari Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 2,200 shares, an increase of 266.7% from the previous total of 600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Akari Therapeutics' float size? Akari Therapeutics currently has issued a total of 7,920,000 shares. Some of Akari Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Akari Therapeutics currently has a public float of 6,590,000 shares. How does Akari Therapeutics' short interest compare to its competitors? 0.03% of Akari Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Akari Therapeutics: Monopar Therapeutics Inc. (1.24%), ABVC BioPharma, Inc. (7.35%), Elevai Labs, Inc. (0.44%), Avalo Therapeutics, Inc. (10.13%), MIRA Pharmaceuticals, Inc. (0.42%), Moleculin Biotech, Inc. (1.45%), Guardion Health Sciences, Inc. (14.33%), Imunon, Inc. (3.95%), Eterna Therapeutics Inc. (1.15%), Aeterna Zentaris Inc. (0.34%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Akari Therapeutics stock? Short selling AKTX is an investing strategy that aims to generate trading profit from Akari Therapeutics as its price is falling. AKTX shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Akari Therapeutics? A short squeeze for Akari Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AKTX, which in turn drives the price of the stock up even further. How often is Akari Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AKTX, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: MNPR Short Interest ABVC Short Interest ELAB Short Interest AVTX Short Interest MIRA Short Interest MBRX Short Interest GHSI Short Interest IMNN Short Interest ERNA Short Interest AEZS Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AKTX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap Profits